At the age of only twelve years, a friend who had helped more than ten million people ®ght obesity, the disease of the century, has suddenly been laid to rest. All that remains is a sense of profound loss and an awareness that we have been deprived of one of our most useful weapons in a battle involving an everincreasing number of patients. Her death was violent and unexpected, sharp and sudden. It is still not clear whether it was due to natural causes, suicide or even murder, but to try to understand better, we now need to analyse the facts.
Created from fen¯uramine, a twin molecule that was born in Europe 35 years ago and has been used by 60 million patients, she ®rst entered the fray in France in 1985. She declared war on obese Americans only last year, and it was in this arduous battle that she lost her own life and caused the death of her progenitor, fen¯uramine. As often happens, bad company can have a bad in¯uence on even the purest spirit, and the young dexfen¯uramine had been seen in the company of phentermine, an old and disreputable relation of amphetamine. The European Health Authorities had attempted to prevent this fatal attraction a long time ago by pronouncing their association as one of the absolute contraindications of both drugs. Nevertheless, in some countries the two continued to meet as they circulated together in the blood of patients for whom they were prescribed as galenic formulations. The Italian authorities forbade this practice as long ago as 1987, and the same action was subsequently taken by many other European countries, and eventually the marketing of phentermine was prohibited in Italy, Germany, France, Spain and Sweden.
In America, where other European-banned drugs (like amphetamine itself) were still available on the market, the association of fen¯uramine and phentermine was looked upon with a more avuncular eye and even given the amusing nickname of Fen-Phen. However this could not hide the terrible havoc that the two could wreak when they were together, which was all too obvious on the basis of a rational assessment of their mechanisms of action, and subsequently con®rmed by clinical experience. Fen¯uramine alters serotonin metabolism and phentermine interferes with the pulmonary clearance of serotonin, and it could be predicted that the combination of the two drugs might increase the concentration andaor potentiate the effects of circulating serotonin. It would not be surprising if this then led to severe cardiovascular side effects, even if the precise process by which this might occur is not known.
The very ®rst data concerning the effects of the combination were presented in Washington and revealed severe side effects affecting memory in 13% of the treated patients. 1 This observation alone would have been enough to justify FDA making provisions similar to those already introduced in Italy. Even although the FDA never actually approved the combination, it never did anything to ban it. As a result, approximately 18 million patients had been already treated with the innocuously sounding FenPhen by the time the August issue of the New England Journal of Medicine published a description of twenty-four cases of echocardiographically-documented morphological and functional damage to cardiac valves. 2 All had been taking Fen-Phen, and ®ve of these patients were also receiving sertraline or¯uox-etine. Given these ®ndings, and despite the fact that there is still no certain proof as to whether it was caused by one of the individual components of the combination or by the combination as such, the manufacturer of dexfen¯uramine and fen¯uramine has responsibly decided to take the precautionary measure of withdrawing them from the world market. Thus, although it would therefore seem to be a case of suicide, only an in-depth retrospective clinical study with appropriate controls can establish the de®nitive truth, and if the victim was pushed to the edge. In the meantime, physicians will remain unarmed for at least a few years until alternative compounds become available.
And so, rest in peace dexfen¯uramineÐeven though, deep down, many of us still hope for your resurrection. Amen. 
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